GeoVax Labs (GOVX) Shares Outstanding (2019 - 2026)
GeoVax Labs (GOVX) posted quarterly Shares Outstanding (Entity) of $4.6 million for Q2 2026, up 616.69% year-over-year from $636984.0 in Q2 2025, and up 376.31% quarter-over-quarter from $958443.0 in Q4 2025.
GeoVax Labs (GOVX) Shares Outstanding (2019 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Shares Outstanding (Entity) for 8 consecutive years, with $4.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 616.69% year-over-year to $4.6 million; the TTM figure through Jun 2026 stood at $4.6 million (up 616.69% YoY), while the FY2025 annual figure was $958443.0, up 361.94% from the prior year.
- Shares Outstanding (Entity) advanced to $4.6 million in Q2 2026 per GOVX's latest filing, from $958443.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $4.6 million in Q2 2026 and bottomed at $18960.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $508411.7 across 5 years, with a median of $92332.0 in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) climbed 1.37% — and 2026, when it soared 616.69%.
- GeoVax Labs' Shares Outstanding (Entity) stood at $45264.0 in 2022, then jumped by 74.72% to $79086.0 in 2023, then jumped by 162.35% to $207482.0 in 2024, then jumped by 361.94% to $958443.0 in 2025, then jumped by 376.31% to $4.6 million in 2026.
- Business Quant data shows GOVX's Shares Outstanding (Entity) at $4.6 million in Q2 2026, $958443.0 in Q4 2025, and $811488.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | 4.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.57 Mn |
| Dec 31, 2025 | 958,443.00 |
| Sep 30, 2025 | 811,488.00 |
| Jun 30, 2025 | 614,369.00 |
| Mar 31, 2025 | 478,192.00 |
| Dec 31, 2024 | 207,482.00 |
| Sep 30, 2024 | 256,192.00 |
| Jun 30, 2024 | 101,595.00 |
| Mar 31, 2024 | 94,682.00 |
| Dec 31, 2023 | 72,691.00 |
| Sep 30, 2023 | 70,788.00 |
| Jun 30, 2023 | 70,520.00 |
| Mar 31, 2023 | 70,240.00 |
| Dec 31, 2022 | 45,264.00 |
| Sep 30, 2022 | 62,568.00 |
| Jun 30, 2022 | 33,926.00 |
| Mar 31, 2022 | 18,960.00 |
| Dec 31, 2021 | 16,267.00 |
| Sep 30, 2021 | 16,932.00 |
| Jun 30, 2021 | 16,862.00 |